RPG Life Sciences Limited (NSE:RPGLIFE)
India · Delayed Price · Currency is INR 2,409.60
-53.50 (-2.17%)
May 11, 2026, 3:29 PM IST
RPG Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 7,075 | 6,534 | 5,821 | 5,128 | 4,402 | |
Revenue Growth (YoY) | 8.28% | 12.26% | 13.50% | 16.50% | 13.11% |
Cost of Revenue | 2,521 | 2,192 | 1,893 | 1,758 | 1,469 |
Gross Profit | 4,554 | 4,342 | 3,928 | 3,370 | 2,932 |
Selling, General & Admin | 1,415 | 1,523 | 1,542 | 1,346 | 1,153 |
Other Operating Expenses | 1,669 | 1,211 | 1,104 | 988.4 | 915.5 |
Operating Expenses | 3,298 | 2,948 | 2,817 | 2,489 | 2,225 |
Operating Income | 1,256 | 1,394 | 1,111 | 881 | 707.4 |
Interest Expense | -8.9 | -6.2 | -4.5 | -3.1 | -5.2 |
Interest & Investment Income | - | 32.1 | 14.2 | 27.3 | 13.3 |
Currency Exchange Gain (Loss) | - | 1.6 | 0.1 | 5 | 7.3 |
Other Non Operating Income (Expenses) | 255.8 | 47.5 | 47.2 | 14.4 | - |
EBT Excluding Unusual Items | 1,503 | 1,469 | 1,168 | 924.6 | 722.8 |
Gain (Loss) on Sale of Investments | - | 12 | 0.1 | - | 8.9 |
Gain (Loss) on Sale of Assets | - | 22.1 | 10.5 | -7.8 | - |
Asset Writedown | -91.6 | - | - | - | - |
Other Unusual Items | 130.6 | 826 | - | - | - |
Pretax Income | 1,542 | 2,329 | 1,178 | 916.8 | 731.7 |
Income Tax Expense | 390.3 | 496.4 | 301.8 | 240.4 | 216.9 |
Earnings From Continuing Operations | 1,152 | 1,832 | 876.6 | 676.4 | 514.8 |
Net Income | 1,152 | 1,832 | 876.6 | 676.4 | 514.8 |
Net Income to Common | 1,152 | 1,832 | 876.6 | 676.4 | 514.8 |
Net Income Growth | -37.15% | 109.03% | 29.60% | 31.39% | 28.70% |
Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 |
Shares Change (YoY) | -0.01% | - | - | - | - |
EPS (Basic) | 69.64 | 110.79 | 53.00 | 40.90 | 31.13 |
EPS (Diluted) | 69.64 | 110.79 | 53.00 | 40.90 | 31.13 |
EPS Growth | -37.14% | 109.03% | 29.60% | 31.39% | 28.70% |
Free Cash Flow | -88.6 | 418.3 | 251.3 | 580.9 | 408 |
Free Cash Flow Per Share | -5.36 | 25.29 | 15.19 | 35.12 | 24.67 |
Dividend Per Share | 24.000 | 20.000 | 16.000 | 12.000 | 9.600 |
Dividend Growth | 20.00% | 25.00% | 33.33% | 25.00% | 33.33% |
Gross Margin | 64.37% | 66.45% | 67.48% | 65.72% | 66.62% |
Operating Margin | 17.75% | 21.33% | 19.08% | 17.18% | 16.07% |
Profit Margin | 16.28% | 28.04% | 15.06% | 13.19% | 11.70% |
Free Cash Flow Margin | -1.25% | 6.40% | 4.32% | 11.33% | 9.27% |
EBITDA | 1,471 | 1,602 | 1,271 | 1,024 | 846.2 |
EBITDA Margin | 20.79% | 24.51% | 21.84% | 19.97% | 19.23% |
D&A For EBITDA | 214.8 | 207.8 | 160.6 | 143 | 138.8 |
EBIT | 1,256 | 1,394 | 1,111 | 881 | 707.4 |
EBIT Margin | 17.75% | 21.33% | 19.08% | 17.18% | 16.07% |
Effective Tax Rate | 25.31% | 21.32% | 25.61% | 26.22% | 29.64% |
Revenue as Reported | 7,331 | 6,661 | 5,893 | 5,176 | 4,432 |
Advertising Expenses | - | 250.4 | 213 | 168.1 | 146.6 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.